Analysts Offer Insights on Industrial Goods Companies: Delta Air Lines (DAL) and JetBlue Airways (JBLU)
Companies in the Industrial Goods sector have received a lot of coverage today as analysts weigh in on Delta Air Lines (DAL) and JetBlue Airways (JBLU).
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Delta Air Lines (DAL)
In a report released today, David Vernon from Bernstein maintained a Buy rating on Delta Air Lines, with a price target of $81.00. The company’s shares closed last Thursday at $66.76, close to its 52-week high of $69.98.
According to TipRanks.com, Vernon is a 4-star analyst with an average return of
Delta Air Lines has an analyst consensus of Strong Buy, with a price target consensus of $80.53, which is a 24.1% upside from current levels. In a report issued on March 23, Citi also maintained a Buy rating on the stock with a $77.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
JetBlue Airways (JBLU)
UBS analyst Atul Maheswari maintained a Sell rating on JetBlue Airways yesterday and set a price target of $3.50. The company’s shares closed last Thursday at $4.52, close to its 52-week low of $4.50.
According to TipRanks.com, Maheswari is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on JetBlue Airways is a Moderate Sell with an average price target of $4.95, a 14.3% upside from current levels. In a report issued on March 26, TipRanks – Anthropic also reiterated a Sell rating on the stock with a $4.50 price target.
Read More on DAL:
Disclaimer & DisclosureReport an Issue
- Delta Air Lines Inc. (DAL) Q1 Earnings Cheat Sheet
- The Week That Was, The Week Ahead: Macro and Markets, April 5
- Ahead of Q1 Earnings, What Do Analysts Make of Delta Air Lines Stock?
- Option traders moderately bearish in Delta Air Lines with shares down 1.32%
- Morning Movers: Immunovant sinks after batoclimab trials miss goal
